Anmelden Kostenlos registrieren

Last updated: 7 March 2024 at 5:36pm EST

Paul Maier Net Worth




The estimated Net Worth of Paul V Maier is at least $445 Tausend dollars as of 15 November 2018. Mr. Maier owns over 5,000 units of Eton Pharmaceuticals stock worth over $286,179 and over the last 21 years he sold ETON stock worth over $30,131. In addition, he makes $128,200 as Independent Director at Eton Pharmaceuticals.

Mr. Maier ETON stock SEC Form 4 insiders trading

Paul has made over 5 trades of the Eton Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of ETON stock worth $30,000 on 15 November 2018.

The largest trade he's ever made was exercising 100,000 units of Eton Pharmaceuticals stock on 8 January 2018 worth over $479,000. On average, Paul trades about 2,969 units every 12 days since 2003. As of 15 November 2018 he still owns at least 59,745 units of Eton Pharmaceuticals stock.

You can see the complete history of Mr. Maier stock trades at the bottom of the page.





Paul Maier biography

Paul V. Maier serves as Independent Director of the Company. Mr. Maier has over 25 years of experience as a senior executive in biotechnology and pharmaceutical companies and more than 15 years of experience as a director of multiple life science public and private company Boards. In addition to his Board positions, Mr. Maier also currently serves as an advisor to the life science industry. In June 2014, Mr. Maier retired after serving since November 2009 as Chief Financial Officer of Sequenom, Inc., a publicly held company serving the discovery, clinical research, and molecular diagnostics market. From February 2007 until November 2009, Mr. Maier served as an independent financial consultant. Previously, Mr. Maier was Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, a position he held from 1992 to 2007. From 1990 to 1992, Mr. Maier served as Vice President, Finance of DFW West, a division of DFS Group, LP a private multinational retailer. From 1984 to 1990, Mr. Maier was employed by ICN Pharmaceuticals, a pharmaceutical and biotechnology research products company, where he held various executive positions in finance and general management in ICN as well as SPI Pharmaceuticals, a publicly held subsidiary. Mr. Maier currently serves on the Board of Directors of International Stem Cell Corporation, Biological Dynamics, and Ritter Pharmaceuticals. He also serves as Vice Chairman of the Board of Lackey Clinic, a non-profit providing healthcare to those without insurance. Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University. Mr. Maier is currently an Executive Partner at The College of William and Mary’s Mason School of Business.

What is the salary of Paul Maier?

As the Independent Director of Eton Pharmaceuticals, the total compensation of Paul Maier at Eton Pharmaceuticals is $128,200. There are 5 executives at Eton Pharmaceuticals getting paid more, with Sean Brynjelsen having the highest compensation of $1,946,410.



How old is Paul Maier?

Paul Maier is 72, he's been the Independent Director of Eton Pharmaceuticals since 2017. There are 1 older and 7 younger executives at Eton Pharmaceuticals. The oldest executive at Eton Pharmaceuticals, Inc. is Charles Casamento, 75, who is the Independent Director.

What's Paul Maier's mailing address?

Paul's mailing address filed with the SEC is C/O AMBRX BIOPHARMA INC., 10975 N TORREY PINES ROAD, LA JOLLA, CA, 92037.

Insiders trading at Eton Pharmaceuticals

Over the last 6 years, insiders at Eton Pharmaceuticals have traded over $20,773,599 worth of Eton Pharmaceuticals stock and bought 488,500 units worth $3,287,585 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum und Health, Inc. Harrow. On average, Eton Pharmaceuticals executives and independent directors trade stock every 61 days with the average trade being worth of $746,905. The most recent stock trade was executed by Sean Brynjelsen on 22 September 2022, trading 10,000 units of ETON stock currently worth $21,000.



What does Eton Pharmaceuticals do?

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.



What does Eton Pharmaceuticals's logo look like?

Eton Pharmaceuticals, Inc. logo

Complete history of Mr. Maier stock trades at Ligand Pharmaceuticals, Ritter Pharmaceuticals, Eton Pharmaceuticals und Ambrx Biopharma

Datum
#
Unternehmen
 Insider
Trans.
Transaktion
 Anzahl der Aktien Preis je Aktie Gesamtpreis Anzahl der Aktien nach Quelle
15 Nov 2018 ETON Eton Pharmaceuticals, Inc. Paul V Maier
Direktor
 Kauf 5,000 $6.00 $30,000
15 Nov 2018
59,745 ↗


Eton Pharmaceuticals executives and stock owners

Eton Pharmaceuticals executives and other stock owners filed with the SEC include: